Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MITHAML

Financiado

Cerrado

MITHAML Exploring the role of Metabolic IntraTumoral Heterogeneity in drug res...

MITHAML Exploring the role of Metabolic IntraTumoral Heterogeneity in drug resistance of Acute Myeloid Leukemia in vivo Drug resistance is a major barrier in acute myeloid leukemia (AML) for which prognosis remains unfavorable. We and others have shown the importance of metabolism in the response to therapies in AML, leading to the development of s... ver más

31/01/2024

INSERM

258K€

Presupuesto del proyecto: 258K€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-01-31

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

INSERM

257.62K€ | Lider

BOARD OF TRUSTEES OF THE LEL...

STANFORD

165.27K€ | Participante

Proyectos interesantes

CTQ2014-56370-R

Medical Technol...

Data Science

120K€ Cerrado

MaGMa

Medical Technol...

Data Science

158K€ Cerrado

EUIN2015-62801

Medical Technol...

Data Science

16K€ Cerrado

CHyMERA

Medical Technol...

Data Science

160K€ Cerrado

SAF2016-80639-P

Medical Technol...

Data Science

218K€ Cerrado

EQC2018-005246-P

Medical Technol...

Data Science

94K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 45 meses Fecha Inicio: 2020-04-02
Fecha Fin: 2024-01-31

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 258K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Drug resistance is a major barrier in acute myeloid leukemia (AML) for which prognosis remains unfavorable. We and others have shown the importance of metabolism in the response to therapies in AML, leading to the development of several drugs targeting mitochondrial functions such as BCL2 inhibitor Venetoclax or Electron Transfer Chain Complex I inhibitor IACS-010759. Tumors are composed of genetically and phenotypically heterogeneous cell populations, not all cells being equal in their ability to respond to treatment. Tremendous advances in single-cell technologies like mass cytometry (CyTOF) have demonstrated a fantastic potential to decipher this phenotypic and signaling heterogeneity. However, metabolic features are mostly measured in bulk, impeding the assessment of the metabolic cellular heterogeneity. We propose to investigate the role of metabolic intratumoral heterogeneity in AML at diagnosis and after new drugs in vivo through 2 aims. First we will determine the relationship between metabolic, signaling and developmental states in healthy and leukemic myeloid bone marrow cells and its link with chemoresistance (Aim 1). Then we will focus on the impact of Venetoclax and IACS on MITH in vivo using patient-derived xenograft mice models to identify specific features related to resistance to these drugs that we will finally therapeutically target with new combinations in vivo (Aim 2). The skills of the experienced researcher (ER) on metabolism and omic technologies and the complementary expertise of the 2 laboratories are key for the success of MITHAML. Indeed, the ER will be trained for 2 years in Dr Davis’s lab (Stanford University, USA), highly recognized in the study of intratumoral heterogeneity especially with CyTOF. She will then bring back these skills in Dr Sarry’s lab (Inserm, France), expert in in vivo AML resistance. This fellowship will be key to help the ER develop the scientific, technological and management skills required for her independence.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores